Sanofi share price gains up to 5%: Exclusive distribution partnership for CNS range with Cipla lifts sentiments.
Sanofi India share price gained more than 5% during the intraday trades on Wednesday. Sanofi India and Cipla Ltd signed exclusive agreement for marketing and distribution of Central Nervous System (CNS) drugs in India.
Cipla, as a part of partnership will handle the distribution of Sanofi India's six CNS brands. These include Frisium®, a well-known brand in the anti-epileptic drug category.
Under the agreement Cipla will make use of its resources and its extensive network of distributors, institutions, strong marketing and sales personnel, and market outreach programs throughout India to increase access to the CNS treatments for patients in need. However Sanofi India will still own, import, and manufacture its whole range of CNS medications across facilities in India and abroad.
Sanofi India a few days back also had announced exclusive distribution and promotion agreement with Emcure Pharmaceuticals Limited for the Sanofi's Cardiovascular products in India, Also read- Suzlon stock jumps over 4% on CRISIL upgrade to 'A-' with positive outlook, signaling financial strength Sanofi India well known for its brands such as Combiflam (pain relief) Allegra (ant -allergic) has a strong range of products catering to the therapeutic range of diabetic care, Cardiology, Anti-histamines, Central Nervous System, vaccines and Thrombosis. Though for Multinational companies certain range of products coming under National List of essential medicines had led to some impact on revenges earlier.
The lower prices however drives volume growth too while annual hikes allowed by the government have been making those brands drive growth,. The marketing agreements with large companies as Cipla will enhance penetration and growth of its products.
. Read more on livemint.com
